Publications and scientific presentations
Posters
- Society for Immunotherapy of Cancer (SITC) Annual Meeting (2024) – Antibody drug conjugate (ADC) payload-induced IL1 suggests potential for anti-IL1RAP therapy combination for enhanced treatment efficacy and prevention of neuropathy
- European Academy of Dermatology & Venereology (EADV) Congress (2024) – Combined blockade of IL-1, IL-33 and IL-36 signaling by targeting IL1RAP to treat inflammatory skin diseases
- ESMO congress (2024) – Phase 1/2 trial shows promising efficacy of nadunolimab in combination with platinum doublets as 2nd line therapy in patients with NSCLC
- ESMO congress (2024) – Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors
- ESMO Gastrointestinal Cancers Congress (2024) – Nadunolimab, a first in class monoclonal antibody against IL1RAP, in advanced pancreatic cancer
- ASCO Annual Meeting (2024) – Impact on chemotherapy induced peripheral neuropathy of nadunolimab, a first in class monoclonal antibody against IL1RAP, in patients with pancreatic cancer, with supportive mouse model data
- 8th Systemic Sclerosis World Congress (2024) – Combined blockade of IL-1, IL-33 and IL-36 signaling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis
- Chemical Biology Workshop: Drug & Biomarker Discovery (2023) – IL1RAP – a future target to reduce vascular inflammation and adhesion?
- ESMO Congress (2023) – Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin (NadGC) in metastatic triple negative breast cancer (mTNBC)
- AACR Special Conference: Pancreatic Cancer (2023) – Interleukin-1 receptor accessory protein (IL1RAP) overexpression is associated with worse prognosis in PDAC and is targetable by nadunolimab
- ASCO Annual Meeting (2023) – Safety, efficacy and biomarker data in non-small cell lung cancer patients treated with the anti-IL1RAP antibody nadunolimab in combination with platinum doublet
- AACR Annual Meeting (2023) – A surrogate to the anti-IL1RAP antibody nadunolimab induces tumor microenvironment changes to the metastatic lung and reduces metastatic lesions in mouse models of metastatic cancer
- AACR Annual Meeting (2023) – Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel
- SITC Annual Meeting (2022) – Nadunolimab inhibits IL-1α/β-induced CXCR1/2 ligand expression and reduces serum levels of CXCL1 and CXCL5 in NSCLC and PDAC patients
- AACR Special Conference: Pancreatic Cancer (2022) – The IL1RAP-blocking antibody nadunolimab disrupts pancreatic cancer cell and fibroblast crosstalk, reduces recruitment of myeloid cells and inhibits tumor growth
- BCVS Scientific Sessions (2022) – A monoclonal antibody blocking interleukin-1 receptor accessory protein reduces acute viral myocarditis severity
- ASCO Annual Meeting (2022) – Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC)
- ASCO Annual Meeting (2022) – Safety, tolerability and preliminary efficacy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in combination with pembrolizumab in subjects with solid tumors
- ASCO Annual Meeting (2022) – Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC)
- European Atherosclerosis Society Congress (2022) – IL1RAP blockade reduces atherosclerosis and limits plaque inflammation
- 7th Systemic Sclerosis World Congress (2022) – Blocking IL1RAP function counteracts pathways associated with human SSc and reduces skin and lung fibrosis in a sclerodermatous GvHD model
- ESMO Congress (2021) – Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC)
- AAI Virtual IMMUNOLOGY (2021) – Blocking IL1, IL33 and IL36 signalling by an anti-IL1RAP antibody is an efficient anti-inflammatory treatment that improves heart function in a model of autoimmune myocarditis
- AACR Annual Meeting (2020) – The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy
- AACR Annual Meeting (2020) – Zebrafish patient tumor-derived xenograft models used for pre-clinical evaluation of CAN04 for lung and pancreatic cancer
- PEGS Europe (2019) – Glycoengineered murine antibodies as surrogates to the humanized and ADCC-enhanced anti-IL1RAP antibody CAN04
- ESMO Congress (2018) – A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumors
- AACR Annual Meeting (2018) – Antibody blockade of IL1RAP signaling reduces metastasis in a breast cancer model
Publications
- Lema et al, Circulation: Heart Failure (2024) – IL1RAP Blockade With a Monoclonal Antibody Reduces Cardiac Inflammation and Preserves Heart Function in Viral and Autoimmune Myocarditis
- Van Cutsem et al, Clinical Cancer Research (2024) – Efficacy and safety of the anti-IL1RAP antibody nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in advanced/metastatic pancreatic cancer
- Fields et al, Cell Reports (2024) – Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling
- Grönberg et al, Annals of the Rheumatic Diseases (2024) – Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis
- Mulholland et al, Cardiovascular Research (2024) – Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation
- Rydberg Millrud et al, Cancer Immunology, Immunotherapy (2022) – Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy
- Fields et al, Frontiers in Immunology (2021) – Molecular basis of selective cytokine signaling inhibition by antibodies targeting a shared receptor
- Robbrecht et al, British Journal of Cancer (2021) – First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours
- Ågerstam et al, Blood (2016) – IL1RAP antibodies block IL1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
- Ågerstam et al, PNAS (2015) – Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia
- Askmyr et al, Blood (2013) – Selective killing of candidate AML stem cells by antibody targeting of IL1RAP
- Järås et al, PNAS (2010) – Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL1 receptor accessory protein
Oral presentations
- ACR Convergence (2022) – Blocking IL-1, IL-33 and IL-36 Signaling with the Anti-IL1RAP Antibody mCAN10 Ameliorates Inflammation and Fibrosis in Preclinical Models of Systemic Sclerosis
- ASCO Annual Meeting (2019) – Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumors
- PEGS (2018) – IL1RAP as a therapeutic target
